LeonaBio (LONA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
10 Mar, 2026Executive summary
Amendment updates the definitive proxy statement for the special meeting scheduled on March 18, 2026, at 8:00 a.m. Pacific Time.
The amendment clarifies the voting treatment for Proposal 6, designating it as a “routine” proposal.
No other changes have been made to the original proxy statement, which remains in effect.
Voting matters and shareholder proposals
Proposal 6 is now classified as a routine proposal, allowing brokers or nominees to vote at their discretion if no instructions are provided by beneficial owners.
Broker non-votes are not expected for Proposal 6 due to its routine status.
No changes to voting standards or the effect of broker non-votes on other proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from LeonaBio
- Shareholders to vote on major share issuances, new equity plan, and increased authorized stock.LONA
Proxy Filing23 Feb 2026 - Shareholders to vote on key share issuances, new equity plan, and major charter amendment.LONA
Proxy Filing4 Feb 2026 - Exclusive lasofoxifene license and $236M financing drive late-stage cancer and ALS programs.LONA
Status Update3 Feb 2026 - Fosgonimeton is tested in a pivotal Alzheimer's trial using GST, with results due in 2H24.LONA
Status Update3 Feb 2026 - Pivotal Alzheimer's trial readout expected in fall, with strong cash position and ALS expansion planned.LONA
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - LIFT Alzheimer's trial nears data, with strong interim results and ALS program advancing.LONA
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Registering 5.5M shares for resale, proceeds to fund cancer and ALS drug development.LONA
Registration Filing20 Jan 2026 - 58.5M shares registered for resale; proceeds from warrants to fund cancer and ALS drug development.LONA
Registration Filing20 Jan 2026 - Shelf registration enables up to $300M in flexible securities offerings for clinical-stage neuro solutions.LONA
Registration Filing16 Dec 2025